Phase I/II trial of cyclophosphamide, mitoxantrone, and escalated doses of carboplatin supported by peripheral-blood stem cells in women with metastatic breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2363-2368

  Patnaik, Amita ^a   MacKinnon, Janet ^a   Goss, Paul ^a   Nagy, Tracy ^a   Stewart, Keith ^a   Keating, Armand ^a   Crump, Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG TOXICITY; NEPHROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0034126558     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2363     Document Type: Article

References (31)

1. Antman KH, Rowlings PA, Vaughan WP, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15:1870-1879, 1997
2. Peters WP: High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1995, pp 215-230
3. Peters WP, Shpall EJ, Jones RB, et al: High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
4. Peters WP, Eder JP, Henner WD, et al: High-dose combination alkylating agents and autologous bone marrow support: A phase I trial. J Clin Oncol 4:646-654, 1986
5. Williams SF, Bitran JD, Kaminer L, et al: A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer. J Clin Oncol 5:260-265, 1987
6. Kennedy MJ, Beveridge R, Rowley S, et al: High-dose chemotherapy with reinfusion of purged autologous bone marrow following intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920-926, 1991
7. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
8. Peters WP, Ross M, Vredenburgh JJ, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
9. Von Hoff DD, Clark GM, Weiss GR, et al: Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. J Clin Oncol 4:1827-1834, 1986
10. Wallerstein R, Spitzer G, Dunphy F, et al: A phase II study of mitoxantrone, etoposide, and thiotepa with autologous bone marrow support for patients with relapsed breast cancer. J Clin Oncol 8:1782-1788, 1990
11. Mulder POM, Sleijfer DT, Willemse PHB, et al: High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous marrow support for refractory solid tumors. Cancer Res 49:4654-4658, 1989
12. Ho AD, Gluck S, Germond C, et al: Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in metastatic breast cancer. Leukemia 7:1738-1746, 1993
13. Nabholtz J-M, Gluck S, Crump M, et al: A pilot phase II study of FAC induction chemotherapy followed by two courses of high-dose polychemotherapy supported with Filgrastim-mobilized peripheral blood progenitor cells (PBPC) in the first line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 15:147a, 1996 (abstr 254)
14. Stiff PJ, McKenzie S, Alberts DS, et al: Phase I clinical and pharmacokinetic study of high-dose mitoxantrone combined with carboplatin, cyclophosphamide, and autologous bone marrow rescue: High response rate for refractory ovarian carcinoma. J Clin Oncol 12:176-183, 1994
15. Wilson WH, Jain V, Bryant G, et al: Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors. J Clin Oncol 10:1712-1722, 1992
16. Coleman RE, Mashiter G, Whitaker KB, et al: Bone scan flare predicts successful systemic therapy for bone metastases. J Nucl Med 29:1354-1359, 1988
17. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
18. Hertenstein B, Stefanic M, Schmeiser T, et al: Cardiac toxicity of bone marrow transplantation: Predictive value of cardiologic evaluation before transplant. J Clin Oncol 12:998-1004, 1994
19. Gardner SF, Lazarus HM, Bednarczyk EM, et al: High-dose cyclophosphamide-induced myocardial damage during BMT: Assessment by positron emission tomography. Bone Marrow Transplant 12:139-144, 1993
20. Braverman AC, Antin JH, Plappert MT, et al: Cyclophosphamide cardiotoxicity in bone marrow transplantation: A prospective evaluation of new dosing regimens. J Clin Oncol 9:1215-1223, 1991
21. Goldberg MA, Antin JH, Guinnan EC, et al: Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 68:1114-1118, 1986
22. Shenkenberg TD, Von Hoff DD: Mitoxantrone: A new anticancer drug with significant clinical activity. Ann Intern Med 105:67-81, 1986
23. Aviles A, Arevila N, Diaz Maqueo JC, et al: Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 11:275-279, 1993
24. Johansen MJ, Madden T, Mehra RC, et al: Phase I pharmacokinetic study of multi-cycle high-dose carboplatin followed by peripheral blood stem-cell infusion in patients with cancer. J Clin Oncol 15:1481-1491, 1997
25. Gisselbrecht C, Extra JM, Lotz JP, et al: Cyclophosphamide mitoxantrone melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 18:857-863, 1996
26. Broun ER, Sridhara R, Sledge GW, et al: Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol 13:2050-2055, 1995
27. Ayash LJ, Elias A, Wheeler C, et al: Double dose-intensive chemotherapy with autologous bone marrow and peripheral blood progenitor cell support for metastatic breast cancer: A feasibility study. J Clin Oncol 12:37-44, 1994
28. Stadtmauer EA, O'Neill A, Goldstein LJ, et al: Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The "Philadelphia" Intergroup study. Proc Am Soc Clin Oncol 18:1a, 1999 (abstr 1)
29. Ballestrero A, Ferrando F, Garuti A, et al: High-dose mitoxantrone with peripheral blood progenitor cell rescue: Toxicity, pharmacokinetics and implications for dosage and schedule. Br J Cancer 76:797-804, 1997
30. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial. J Clin Oncol 13:2483-2489, 1995
31. Crump M, Gluck S, Pritchard K, et al: High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 16:800-801, 1998.